uracil has been researched along with Nasopharyngeal Neoplasms in 9 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
Nasopharyngeal Neoplasms: Tumors or cancer of the NASOPHARYNX.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 7.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
| "The study was aimed to evaluate the impact of accumulated oral tegafur-uracil (UFUR) as maintenance chemotherapy on overall survival (OS) and disease-free survival (DFS) rates after concurrent chemoradiotherapy (CCRT) for complete remission (CR) in non-distant metastatic TNM stage IV nasopharyngeal carcinoma (NPC)." | 3.91 | Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma. ( Chao, TY; Chen, JH; Ho, CL; Huang, WY; Lee, JC, 2019) |
| "Distant metastases rate (DMR) was significantly reduced with CRT (14." | 2.71 | Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study. ( Au, GK; Chan, RT; Cheng, AC; Choy, DD; Chua, DT; Kwok, CC; Kwong, DL; Kwong, PW; Law, MW; Sham, JS; Wan, KY; Wu, PM; Yau, CC, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (44.44) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (33.33) | 29.6817 |
| 2010's | 2 (22.22) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, JH | 1 |
| Huang, WY | 1 |
| Ho, CL | 1 |
| Chao, TY | 1 |
| Lee, JC | 1 |
| Twu, CW | 1 |
| Wang, WY | 1 |
| Chen, CC | 1 |
| Liang, KL | 1 |
| Jiang, RS | 1 |
| Wu, CT | 1 |
| Shih, YT | 1 |
| Lin, PJ | 1 |
| Liu, YC | 1 |
| Lin, JC | 1 |
| Okita, J | 1 |
| Hatta, C | 1 |
| Terada, T | 1 |
| Saeki, N | 1 |
| Ogasawara, H | 1 |
| Kakibuchi, M | 1 |
| Kamikonya, N | 1 |
| Sakagami, M | 1 |
| Kwong, DL | 1 |
| Sham, JS | 1 |
| Au, GK | 1 |
| Chua, DT | 1 |
| Kwong, PW | 1 |
| Cheng, AC | 1 |
| Wu, PM | 1 |
| Law, MW | 1 |
| Kwok, CC | 1 |
| Yau, CC | 1 |
| Wan, KY | 1 |
| Chan, RT | 1 |
| Choy, DD | 1 |
| Park, JH | 1 |
| Nam, SY | 1 |
| Lee, SW | 1 |
| Kim, SB | 1 |
| Kim, SY | 1 |
| Lee, BJ | 1 |
| Cho, KJ | 1 |
| Kim, JH | 1 |
| Ahn, SD | 1 |
| Shin, SS | 1 |
| Choi, SH | 1 |
| Ahn, JH | 1 |
| Choi, EK | 1 |
| Tsujii, H | 1 |
| Kamada, T | 1 |
| Tsuji, H | 1 |
| Takamura, A | 1 |
| Matsuoka, Y | 1 |
| Usubuchi, H | 1 |
| Irie, G | 1 |
| Furukawa, M | 2 |
| Ohoka, H | 2 |
| Sakashita, H | 1 |
| Umeda, R | 2 |
| Kamide, M | 1 |
| Comorosan, S | 1 |
| Vieru, S | 1 |
| Gaspar, A | 1 |
| Sandru, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Single-agent Capecitabine as Adjuvant Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase 3, Multicentre, Randomised Controlled Trial (CAN)[NCT02958111] | Phase 3 | 406 participants (Actual) | Interventional | 2017-01-31 | Active, not recruiting | ||
| Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma[NCT03925090] | Phase 2 | 150 participants (Anticipated) | Interventional | 2019-12-08 | Active, not recruiting | ||
| Phase Ⅲ Trial of Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy (GP Versus PF) in Patients With N2-3 Nasopharyngeal Carcinoma[NCT03321539] | Phase 3 | 216 participants (Anticipated) | Interventional | 2017-10-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for uracil and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Concurrent and adjuvant chemotherapy for nasopharyngeal carcinoma: a factorial study.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcin | 2004 |
8 other studies available for uracil and Nasopharyngeal Neoplasms
| Article | Year |
|---|---|
Evaluation of oral tegafur-uracil as metronomic therapy following concurrent chemoradiotherapy in patients with non-distant metastatic TNM stage IV nasopharyngeal carcinoma.
Topics: Administration, Metronomic; Administration, Oral; Adult; Antimetabolites, Antineoplastic; Chemoradio | 2019 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Metronomic adjuvant chemotherapy improves treatment outcome in nasopharyngeal carcinoma patients with postradiation persistently detectable plasma Epstein-Barr virus deoxyribonucleic acid.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Chemotherapy, Adjuvant; Cisplatin | 2014 |
Concurrent chemo-radiotherapy for nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Car | 2004 |
Radiation therapy with UFT and low dose weekly cisplatin for nasopharyngeal carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Co | 2005 |
Improved results in the treatment of nasopharyngeal carcinoma using combined radiotherapy and chemotherapy.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Carcinoma, | 1989 |
Synergistic antitumor activity of cisplatin and UFT in nude mice bearing transplantable nasopharyngeal hybridoma.
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Drug Administration S | 1989 |
[Combination chemotherapy with cisplatin and UFT malignant tumors of the head and neck--experimental study of human nasopharyngeal carcinoma (A2L/AH) xenografted to nude mice].
Topics: Administration, Oral; Animals; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Drug Admin | 1988 |
Nucleic acids and protein biosynthesis during alkylation with triethylenemelamine in kb-cells.
Topics: Absorption; Adenine; Alkylation; Arginine; Carbon Isotopes; Carcinoma, Squamous Cell; Culture Techni | 1968 |